– USA, MA – Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing a range of product candidates derived from its oncolytic immuno-gene therapy platform, today announced the appointment of Christy Oliger to its Board of Directors, effective December 1, 2021.
“We are delighted to welcome Christy to Replimune’s Board of Directors. Christy brings nearly 30 years of commercial and business experience in the pharmaceutical and biotechnology industry foremostly in oncology. We look forward to working with Christy and believe her guidance and input will strengthen our board as we advance our leading pipeline of oncolytic immunotherapies to market,” said CEO, Philip Astley-Sparke.
About Christy Oliger
Christy Oliger was SVP of the Oncology Business Unit at Genentech responsible for all commercial activities in the US. Ms. Oliger spent two decades with Genentech, holding several leadership roles including SVP, IMPACT Business Unit; VP, Pharma Portfolio Management; VP, Portfolio Planning and VP, Hematology Marketing and Sales. Before Genentech, Ms. Oliger held management positions at Schering-Plough. Ms. Oliger currently serves as a member of the board of Karyopharm Therapeutics Inc., Reata Pharmaceuticals, Inc., and Sierra Oncology, Inc.
Ms. Oliger holds a bachelor’s degree in Economics from the University of California at Santa Barbara.
About Replimune
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of the immune response to the tumor antigens released. Replimune’s Immulytic® platform is designed to maximize systemic immune activation, in particular to tumor neoantigens, through robust viral-mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune-activating proteins to the tumor and draining lymph nodes. The approach is expected to be highly synergistic with immune checkpoint blockade and other approaches to cancer treatment across a broad range of cancers. Replimune intends to progress these therapies rapidly through clinical development in combination with other immuno-oncology products with complementary mechanisms of action as well as in standalone indications.
For more information: https://replimune.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
